Sumatriptan Clinical Pharmacokinetics
- 88 Downloads
Sumatriptan is a novel serotonini (5-hydroxytryptamine1; 5-HT1)-like agonist which has been shown to be effective in the treatment of acute migraine. Single-dose pharmacokinetic studies reflect the way that sumatriptan will be used in routine practice, but relatively few studies have been published.
Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. After oral administration, multiple peak concentrations are observed, but a concentration that is 75% of the final peak concentration is usually reached within 45 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.
The pharmacokinetic profile of sumatriptan is not significantly affected by an acute migraine attack (absorption phase), old age or gender. Pharmacokinetic studies in individuals with hepatic and renal disease have not been published; however, care should be taken when sumatriptan is administered to patients with liver disease until such information is available. No significant interaction was found between sumatriptan and propranolol, flunarizine, pizotifen or alcohol (ethanol).
Unable to display preview. Download preview PDF.
- 1.Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39: 737–63Google Scholar
- 9.Gutterman DL, Plachetka JR, Donn K, et al. Evaluation of the safety and pharmacokinetic properties of single subcutaneous doses of GR43175c in healthy, adult, male volunteers. Cephalalgia 1989; 9 Suppl. 10: 412–3Google Scholar
- 10.Busch MA, Plachetka JR, Donn KH, et al. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR 43175 administered to healthy male volunteers. Cephalalgia 1989; 9 Suppl. 10: 414–5Google Scholar
- 14.Dixon CM, Saynor DA, Halliday TJ, et al. The disposition of sumatriptan in animals and man. Poster presented at Imigran: planning a revolution. Imigran Medical Marketing Symposium: 1990 Sept; Westminster, LondonGoogle Scholar
- 15.Cutler NR, Hussey EK, Sramek JJ, et al. Pharmacokinetics of oral sumatriptan in migraine patients during an attack and while pain free [abstract]. Biol Psychiatry 1992; 31: 180AGoogle Scholar
- 16.Glaxo. Sumatriptan prescribing information, United Kingdom, 1994Google Scholar
- 18.Fowler PA, Lacey LF, Keene ON, et al. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia 1991; 11 Suppl. 11: 228–9Google Scholar
- 19.Kempsford RD, Lacey LF, Thomas M, et al. The effect of alcohol on the pharmacokinetic profile of oral sumatriptan [abstract]. Fundam Clin Pharmacol 1991; 5: 470Google Scholar